Advancement in 3D printing technology has widely reshaped the industry dynamics along various verticals ranging from automation to healthcare. 3D printed organs are the next generation organ transplantation technology reshaping the overall healthcare industry. This million dollar industry is growing at a robust double digit growth rate creating new market opportunities for medical players. Demand for organ transplants has increased in last five years. As per the estimates of U.S. National Kidney Foundation, there are nearly 121 thousand people waiting for lifesaving organ transplants. Of these, 80% are kidney transplant seekers. More than 650 thousand transplants have occurred in the U.S. in last 28 years. However, the numbers are in sharp contrast to actual demand and there is huge gap between supply and demand of organs. Only 2% of cases are met with organ transplants. Increasing demand has led to high impetus on development of technology to artificially build lifesaving organs. As a result, many companies in collaboration with R&D institutes are engaged in development of 3D printed organs.
3D bioprinting is set to revolutionize the healthcare industry in coming years and will be widely used for transplantation of several tissues including vascular grafts, tracheal splints, heart tissue, etc. Early entrants in the market will give added advantage to players and will help in excelling business revenue to a larger extent.
Coherent Market Insights has segmented the market by
Demand for functional 3d printed tissue is expected to grow at a robust rate owing to high demand for lifesaving organ coupled with changing healthcare macroeconomics. Many university labs such as Wake Forest Institute for Regenerative Medicine and Harvard scientist in collaboration with leading medical device companies are carrying out projects to develop lab-grown tissue to meet the growing demand of millions seeking for organ transplantation. Advent of 3d printing technology has bridged the gap to a great extent. The market is further driven by growing consumer base and increasing healthcare expenditure.
Though the market is positive, the industry is currently undergoing through some challenges namely – high cost incurred on research and development outcomes along with regulatory pressures. The technology will take at least 7 years to fully commercialize resulting in high operating cost. As such, funding from government bodies could ease out the industry pressure.
By application, the functional 3d printed tissue is segmented into organ transplants, dental and biosensors. Organ transplant application segment is expected to dominate the market throughout the forecast period with over 65% of the market by end of forecast period.
Among regions, North America and Europe are expected to dominate the market throughout the forecast period. Moreover, North America is expected to grow at a fastest rate owing to high spending on R&D and presence of leading companies in the region. Moreover, the region accounts for highest number of organ transplant surgeries carried out in last five years – highest worldwide.
As per the initial study carried out by CA, North America and Europe are expected to account for over 85% of overall functional 3d printed tissue market. Healthcare providers are seeking this technology to manage the growing demand for organ transplant in the country. Growth in these regions is expected to be further driven by macroeconomic factors. The region as a whole spends over 5% of its GDP on research and GDP. Moreover, healthcare spending is highest in this region with North America accounting for 16.7% and Europe 10% of overall GDP in 2015.
Asia Pacific is expected to be driven by Australia and Japan. According to Organdonor, donation rate in Australia is nearly 17 per million populations. The country is pioneer in the field of 3d bioprinting research. Griffith University's Menzies Institute in support with National Health and Medical Research Council is taking step towards creation of 3d printed tissue and bones. Moreover, the initiative taken by Australian government towards setting up of US$ 2.7 Mn bioprinting center will boost the overall market in near future. Market in the region is expected to commercialize in next 15 years. The region is at nascent stage and will take years to commercialize. Most of the projects are expected to be at preliminary stage till the forecast period.
Some key players engaged in the market are Aspect Biosystems, BioBots TeVido, Organovo, Cyfuse Biomedical, 3Dynamics Systems, Luxexcel Group, Stratasys, EnvisionTEC, etc.
Major companies in the market are focused on raising funds to expand their product portfolio. For instance, in July 2019, U.S.-based biotechnology company, Prellis Biologics raised US$ 8.7 million to advance its holographic 3D bioprinting platform.
Major institutes are also focused on research and development activities related to 3D printing of tissues. For instance, in August, researchers from Laboratory of Applied Photonics Devices (LAPD), in EPFL's School of Engineering, in collaboration with Utrecht University, reported development of a technique called volumetric bioprinting to produce complex tissue forms in hydrogels, which are loaded with stem cells to generate growth of blood vessels in the resulting tissue mass.
Similarly, in April 2019, researchers from Indian Institute of Technology Hyderabad, India used discarded eel skins to fabricate 3D scaffolds for tissue engineering application.